4D Molecular Therapeutics Files 8-K Report
Ticker: FDMT · Form: 8-K · Filed: Sep 18, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
4D Molecular Therapeutics filed an 8-K, likely a material event. Details to follow.
AI Summary
On September 18, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Emeryville, California.
Why It Matters
This filing signals a material event has occurred for 4D Molecular Therapeutics, Inc., requiring disclosure to investors.
Risk Assessment
Risk Level: medium — An 8-K filing indicates a significant event, but the lack of specific details in the provided text creates uncertainty.
Key Numbers
- 001-39782 — Commission File Number (Identifies the company's SEC filing history.)
- 47-3506994 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- September 18, 2024 (date) — Date of Report
- Emeryville, California (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific event is reported in this 8-K filing?
The provided text indicates an 'Other Event' but does not specify the nature of the event.
When was this 8-K report filed?
The report was filed on September 18, 2024.
What is the principal business address of 4D Molecular Therapeutics, Inc.?
The principal executive offices are located at 5858 Horton Street #455, Emeryville, California, 94608.
In which state is 4D Molecular Therapeutics, Inc. incorporated?
The company is incorporated in Delaware.
What is the SIC code for 4D Molecular Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836 for Biological Products (No Diagnostic Substances).
Filing Stats: 1,085 words · 4 min read · ~4 pages · Grade level 13.8 · Accepted 2024-09-18 16:06:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
Filing Documents
- d865019d8k.htm (8-K) — 37KB
- 0001193125-24-221375.txt ( ) — 159KB
- fdmt-20240918.xsd (EX-101.SCH) — 3KB
- fdmt-20240918_lab.xml (EX-101.LAB) — 18KB
- fdmt-20240918_pre.xml (EX-101.PRE) — 11KB
- d865019d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company's clinical development plans for 4D-150 and timing for the announcement of results from ongoing clinical trials. In some cases you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "expect" or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: September 18, 2024 By: /s/ Uneek Mehra Uneek Mehra Chief Financial and Business Officer